Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of LY500307 in men with LUTS and BPH-related prostatic enlargement
2009-016800-22Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in benign prostatic hyperplasia (BPH) comparing LY500307 once daily with Placebo once daily (2 arms). Primary endpoint: Change in IPSS total score. Started Mar 2010; status: completed.
02
Drugs
erteberel
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on 2009-016800-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016800-22.